

## This week in techniques

Approach	Summary	Licensing status	Publication and contact information
<b>Markers</b>			
Intercellular adhesion molecule-1 (ICAM-1; CD54) as a marker of treatment response for congenital disorders of glycosylation	<p>Patient sample studies suggest ICAM-1 could be useful as a marker for congenital disorders of glycosylation, which are caused by inherited genetic defects in N-linked glycosylation. In patient fibroblasts, ICAM-1 levels were lower than those in normal cells. In one of the patient cell lines, addition of mannose, which relieves disease symptoms, increased ICAM-1 expression compared with no addition. Next steps include testing ICAM-1 as a marker for detecting improvements in glycosylation activity in cells.</p> <p><b>SciBX 5(17); doi:10.1038/scibx.2012.454</b> Published online April 26, 2012</p>	<p>Provisional patent application filed; available for licensing from the Sanford-Burnham Medical Research Institute <b>Contact:</b> Paul Laikind, Sanford-Burnham Medical Research Institute, La Jolla, Calif. phone: 858-646-3116 e-mail: <a href="mailto:plaikind@sanfordburnham.org">plaikind@sanfordburnham.org</a></p>	<p>He, P. <i>et al.</i> <i>J. Biol. Chem.</i>; published online April 11, 2012; doi:10.1074/jbc.M112.355677 <b>Contact:</b> Hudson H. Freeze, Sanford-Burnham Medical Research Institute, La Jolla, Calif. e-mail: <a href="mailto:HUDSON@SANFORDBURNHAM.ORG">HUDSON@SANFORDBURNHAM.ORG</a></p>